US panel urges more safety tests of diabetes drugs
SILVER SPRING, Md., July 2 (Reuters) - U.S. regulators should require more testing of the potential heart risks of new diabetes medicines, an advisory panel said on Wednesday.
By a 14-2 vote, the advisers to the Food and Drug Administration recommended companies conduct a long-term study or provide equivalent evidence to rule out an unacceptable risk of heart problems for proposed new diabetes medicines.
Some data could be collected before approval with additional results provided after the drug reaches the market, several panel members said. (Reporting by Lisa Richwine; editing by Tim Dobbyn)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Manimals
McCain promises change for America